We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Regeneron (REGN - Free Report) closed at $706.11 in the latest trading session, marking a -1.88% move from the prior day. This change lagged the S&P 500's 1.48% loss on the day. Meanwhile, the Dow lost 1.05%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Heading into today, shares of the biopharmaceutical company had gained 7.53% over the past month, outpacing the Medical sector's gain of 0.83% and the S&P 500's gain of 0.08% in that time.
Wall Street will be looking for positivity from Regeneron as it approaches its next earnings report date. This is expected to be May 4, 2022. In that report, analysts expect Regeneron to post earnings of $9.73 per share. This would mark a year-over-year decline of 1.62%. Meanwhile, our latest consensus estimate is calling for revenue of $2.67 billion, up 5.51% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $44.45 per share and revenue of $11.51 billion, which would represent changes of -40.46% and -28.37%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Regeneron. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.17% lower. Regeneron is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 16.19 right now. Its industry sports an average Forward P/E of 23.34, so we one might conclude that Regeneron is trading at a discount comparatively.
Investors should also note that REGN has a PEG ratio of 1.25 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.31 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
Regeneron (REGN - Free Report) closed at $706.11 in the latest trading session, marking a -1.88% move from the prior day. This change lagged the S&P 500's 1.48% loss on the day. Meanwhile, the Dow lost 1.05%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Heading into today, shares of the biopharmaceutical company had gained 7.53% over the past month, outpacing the Medical sector's gain of 0.83% and the S&P 500's gain of 0.08% in that time.
Wall Street will be looking for positivity from Regeneron as it approaches its next earnings report date. This is expected to be May 4, 2022. In that report, analysts expect Regeneron to post earnings of $9.73 per share. This would mark a year-over-year decline of 1.62%. Meanwhile, our latest consensus estimate is calling for revenue of $2.67 billion, up 5.51% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $44.45 per share and revenue of $11.51 billion, which would represent changes of -40.46% and -28.37%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Regeneron. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.17% lower. Regeneron is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Regeneron has a Forward P/E ratio of 16.19 right now. Its industry sports an average Forward P/E of 23.34, so we one might conclude that Regeneron is trading at a discount comparatively.
Investors should also note that REGN has a PEG ratio of 1.25 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.31 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.